3-(phenylamino)alanine | 219638-86-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(phenylamino)alanine
• 英文别名: 2-amino-3-phenylamino-propionic acid；2-Amino-3-(phenylamino)propanoic acid；2-amino-3-anilinopropanoic acid
• CAS: 219638-86-5
• 化学式: C₉H₁₂N₂O₂
• 分子量: 180.206
• InChiKey: HLZOBKHLQBRIJP-UHFFFAOYSA-N

物化性质

• 沸点：
  406.7±40.0 °C(Predicted)
• 密度：
  1.281±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  75.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(phenylamino)alanine 在 盐酸 作用下， 以 乙腈 为溶剂， 反应 0.5h， 生成 3-Phenylamino-2-(trimethylsilanyl-amino)-propionic acid methyl ester
  参考文献：
  名称：

  Identification of four metabolites of 3-(phenylamino)alanine, a constituent in l-tryptophan products implicated in eosinophiliamyalgia syndrome, in rats

  摘要：

  3-(Phenylamino)alanine (PAA), a contaminant found in L-tryptophan tablets, has been discussed as a possible cause of eosinophilia-myalgia syndrome (EMS). We administered PAA (100 mg/kg) by gastric gavage to Wistar rats to determine its distribution and metabolism. We developed a purification procedure, using Bond Elut SCX cartridges followed by high performance liquid chromatography (HPLC) in order to determine levels of PAA. The level of PAA in blood was 4.22 mu g/ml at 5 h and urinary excretion was 21.7 mu g for 5 h and 84.6 mu g between 5 and 24 h. The amount of PAA in the contents of the large intestine at 5 h was 0.76 mu g, indicating poor transfer of PAA to the large intestine. However, the highest concentration of PAA was 12.3 mu g/g in the brain, indicating the passage of PAA through the blood-brain barrier. In addition to detecting PAA in the blood and organs, we also detected four metabolites of PAA in urine. We used gas chromatography mass spectrometry to identify PAA in rat liver, as well as N-(hydroxyphenyl)glycine, N-phenylglycine, 3-(pheylamino)lactic acid, and 3-(hydroxyphenylamino)lactic acid in rat urine. These results suggest that the degradation pathway of PAA is similar to that of phenylalanine.

  DOI：

  10.1007/s002040050102
• 作为产物：
  描述：

  DL-丝氨酸 、 苯胺 以 水 为溶剂， 反应 6.0h， 生成 3-(phenylamino)alanine
  参考文献：
  名称：

  Toyoda, Masatake; Saito, Yukio; Uchiyama, Mitsuru, Bioscience, Biotechnology and Biochemistry, 1994, vol. 58, # 7, p. 1318 - 1320

  摘要：

  DOI：

文献信息

• UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa
  申请人：KALLUS Christopher

  公开号：US20100035930A1

  公开（公告）日：2010-02-11

  The invention relates to compounds of the formula I as defined herein, which are inhibitors of activated thrombin-activatable fibrinolysis inhibitor. The compounds of the formula I are suitable for manufacturing medicaments for the prophylaxis, secondary prevention and therapy of one or more disorders which are associated with thromboses, embolisms, hypercoagulability or fibrotic changes.

  这项发明涉及到本处定义的公式I的化合物，这些化合物是活化的凝血酶可激活纤溶抑制剂的抑制剂。公式I的化合物适用于制造用于预防、次级预防和治疗与血栓形成、栓塞、高凝状态或纤维变化相关的一个或多个疾病的药物。
• Substituted indoles
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20030119820A1

  公开（公告）日：2003-06-26

  Compounds of the formula I 1 are suitable for preparing pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of NF&kgr;B is involved.

  式I1的化合物适用于制备用于预防和治疗涉及NF&kgr;B增加活性的疾病的药物。
• Use of IkappaB-kinase inhibitors in pain therapy
  申请人：AVENTIS PHARMA DEUTSCHLAND GMBH

  公开号：US20040116494A1

  公开（公告）日：2004-06-17

  The present invention relates to the use of I&kgr;B-kinase Inhibitors and methods for the prophylaxis and therapy for treating pain comprising administering such compounds.

  本发明涉及使用I&kgr;B-激酶抑制剂和治疗方法，用于预防和治疗疼痛，包括给予这些化合物。
• Use of IKappaB-Kinase Inhibitors in Pain Therapy
  申请人：MICHAELIS Martin

  公开号：US20090069358A1

  公开（公告）日：2009-03-12

  The present invention relates to the use of IκB-kinase Inhibitors and methods for the prophylaxis and therapy for treating pain comprising administering such compounds.

  本发明涉及使用IκB-激酶抑制剂以及治疗疼痛的预防和治疗方法，包括给予这些化合物。
• SUBSTITUIERTE BENZIMIDAZOLE
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1194425B1

  公开（公告）日：2005-08-10